Literature DB >> 17640595

Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.

Siok-Keen Tey1, Gianpietro Dotti, Cliona M Rooney, Helen E Heslop, Malcolm K Brenner.   

Abstract

Addback of donor T cells following T cell-depleted stem cell transplantation (SCT) can accelerate immune reconstitution and be effective against relapsed malignancy. After haploidentical SCT, a high risk of graft-versus-host disease (GVHD) essentially precludes this option, unless the T cells are first depleted of alloreactive precursor cells. Even then, the risks of severe GVHD remain significant. To increase the safety of the approach and thereby permit administration of larger T cell doses, we used a suicide gene, inducible caspase 9 (iCasp9), to transduce allodepleted T cells, permitting their destruction should administration have adverse effects. We made a retroviral vector encoding iCasp9 and a selectable marker (truncated CD19). Even after allodepletion (using anti-CD25 immunotoxin), donor T cells could be efficiently transduced, expanded, and subsequently enriched by CD19 immunomagnetic selection to >90% purity. These engineered cells retained antiviral specificity and functionality, and contained a subset with regulatory phenotype and function. Activating iCasp9 with a small-molecule dimerizer rapidly produced >90% apoptosis. Although transgene expression was downregulated in quiescent T cells, iCasp9 remained an efficient suicide gene, as expression was rapidly upregulated in activated (alloreactive) T cells. We have demonstrated the clinical feasibility of this approach after haploidentical transplantation by scaling up production using clinical grade materials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640595      PMCID: PMC2040267          DOI: 10.1016/j.bbmt.2007.04.005

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  36 in total

1.  CD34 splice variant: an attractive marker for selection of gene-modified cells.

Authors:  B Fehse; A Richters; K Putimtseva-Scharf; H Klump; Z Li; W Ostertag; A R Zander; C Baum
Journal:  Mol Ther       Date:  2000-05       Impact factor: 11.454

2.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.

Authors:  Carolina Berger; Mary E Flowers; Edus H Warren; Stanley R Riddell
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

4.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

Authors:  P Tiberghien; C Ferrand; B Lioure; N Milpied; R Angonin; E Deconinck; J M Certoux; E Robinet; P Saas; B Petracca; C Juttner; C W Reynolds; D L Longo; P Hervé; J Y Cahn
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

5.  Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy.

Authors:  Mariana Mesel-Lemoine; Mustapha Cherai; Sabine Le Gouvello; Maude Guillot; Virginie Leclercq; David Klatzmann; Véronique Thomas-Vaslin; François M Lemoine
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

6.  Long-term outcome after haploidentical stem cell transplantation in children.

Authors:  Peter Lang; Johann Greil; Peter Bader; Rupert Handgretinger; Thomas Klingebiel; Michael Schumm; Paul-Gerhard Schlegel; Tobias Feuchtinger; Matthias Pfeiffer; Hans Scheel-Walter; Monika Führer; David Martin; Dietrich Niethammer
Journal:  Blood Cells Mol Dis       Date:  2004 Nov-Dec       Impact factor: 3.039

7.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

Authors:  Franco Aversa; Adelmo Terenzi; Antonio Tabilio; Franca Falzetti; Alessandra Carotti; Stelvio Ballanti; Rita Felicini; Flavio Falcinelli; Andrea Velardi; Loredana Ruggeri; Teresa Aloisi; Jean Pierre Saab; Antonella Santucci; Katia Perruccio; Maria Paola Martelli; Cristina Mecucci; Yair Reisner; Massimo F Martelli
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

8.  Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Authors:  Persis J Amrolia; Giada Muccioli-Casadei; Helen Huls; Stuart Adams; April Durett; Adrian Gee; Eric Yvon; Heidi Weiss; Mark Cobbold; H Bobby Gaspar; Cliona Rooney; Ingrid Kuehnle; Victor Ghetie; John Schindler; Robert Krance; Helen E Heslop; Paul Veys; Ellen Vitetta; Malcolm K Brenner
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

9.  Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.

Authors:  Attilio Bondanza; Veronica Valtolina; Zulma Magnani; Maurilio Ponzoni; Katharina Fleischhauer; Mark Bonyhadi; Catia Traversari; Francesca Sanvito; Salvatore Toma; Marina Radrizzani; Simona La Seta-Catamancio; Fabio Ciceri; Claudio Bordignon; Chiara Bonini
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

10.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.

Authors:  C Bonini; G Ferrari; S Verzeletti; P Servida; E Zappone; L Ruggieri; M Ponzoni; S Rossini; F Mavilio; C Traversari; C Bordignon
Journal:  Science       Date:  1997-06-13       Impact factor: 47.728

View more
  104 in total

1.  Live and let die: a new suicide gene therapy moves to the clinic.

Authors:  Richard A Morgan
Journal:  Mol Ther       Date:  2012-01       Impact factor: 11.454

Review 2.  Designing T cells for cancer immunotherapy.

Authors:  Leslie E Huye; Gianpietro Dotti
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

3.  T cell receptors and cancer: gain gives pain.

Authors:  Malcolm Brenner
Journal:  Nat Med       Date:  2010-05       Impact factor: 53.440

4.  Safer CARS.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

Review 5.  Genetic modification of T cells.

Authors:  Chiara Bonini; Malcolm K Brenner; Helen E Heslop; Richard A Morgan
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

6.  An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.

Authors:  Carlos Almeida Ramos; Zahra Asgari; Enli Liu; Eric Yvon; Helen E Heslop; Clio M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

7.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 8.  T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.

Authors:  Melinda A Biernacki; Michelle Brault; Marie Bleakley
Journal:  Cancer J       Date:  2019 May/Jun       Impact factor: 3.360

Review 9.  Adoptive T cell therapy of cancer.

Authors:  Malcolm K Brenner; Helen E Heslop
Journal:  Curr Opin Immunol       Date:  2010-02-17       Impact factor: 7.486

10.  Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.

Authors:  Xiuli Wang; Araceli Naranjo; Christine E Brown; Cherrilyn Bautista; Chinglam W Wong; Wen-Chung Chang; Brenda Aguilar; Julie R Ostberg; Stanley R Riddell; Stephen J Forman; Michael C Jensen
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.